Soluble tumour necrosis factor receptor type II and survival in colorectal cancer

[1]  S. Sanyal,et al.  Activation of NF-κB: bridging the gap between inflammation and cancer in colitis-mediated colon carcinogenesis. , 2014, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[2]  R. Detels,et al.  Temporal Stability of Serum Concentrations of Cytokines and Soluble Receptors Measured Across Two Years in Low-Risk HIV-Seronegative Men , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[3]  P. Lance,et al.  TNFα‐activated stromal COX‐2 signalling promotes proliferative and invasive potential of colon cancer epithelial cells , 2013, Cell proliferation.

[4]  J. Murabito,et al.  Multiple Inflammatory Biomarkers in Relation to Cardiovascular Events and Mortality in the Community , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[5]  S. Lai,et al.  Aspirin Use After Diagnosis Improves Survival in Older Adults with Colon Cancer , 2013, Journal of the American Geriatrics Society.

[6]  E. Giovannucci,et al.  A prospective study of plasma inflammatory markers and risk of colorectal cancer in men , 2013, British Journal of Cancer.

[7]  Reiko Nishihara,et al.  Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. , 2012, The New England journal of medicine.

[8]  M. Ziepert,et al.  Circulating Levels of TNF Receptor II Are Prognostic for Patients with Peripheral T-cell Non–Hodgkin Lymphoma , 2012, Clinical Cancer Research.

[9]  P. Rothwell,et al.  Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. , 2012, The Lancet. Oncology.

[10]  Kathryn E. Hamilton,et al.  Cytokine Induction of Tumor Necrosis Factor Receptor 2 Is Mediated by STAT3 in Colon Cancer Cells , 2011, Molecular Cancer Research.

[11]  P. Kant,et al.  Excess body weight and obesity—the link with gastrointestinal and hepatobiliary cancer , 2011, Nature Reviews Gastroenterology &Hepatology.

[12]  E. Giovannucci,et al.  Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. , 2011, Gastroenterology.

[13]  Miriam Davis,et al.  TNF receptor 2 pathway: drug target for autoimmune diseases , 2010, Nature Reviews Drug Discovery.

[14]  S. Ogino,et al.  Aspirin Use and Survival After Diagnosis of Colorectal Cancer , 2009 .

[15]  O. Kowalczuk,et al.  Circulating levels of TNF-alpha and its soluble receptors in the plasma of patients with epithelial ovarian cancer. , 2009, European cytokine network.

[16]  B Rosner,et al.  Determination of blood pressure percentiles in normal-weight children: some methodological issues. , 2008, American journal of epidemiology.

[17]  N. Mukaida,et al.  Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. , 2008, The Journal of clinical investigation.

[18]  J. Manson,et al.  A prospective study of inflammatory cytokines and diabetes mellitus in a multiethnic cohort of postmenopausal women. , 2007, Archives of internal medicine.

[19]  F. Klebl,et al.  Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients , 2007, Inflammatory bowel diseases.

[20]  S. Solomon,et al.  Celecoxib for the prevention of sporadic colorectal adenomas. , 2006, The New England journal of medicine.

[21]  S. Solomon,et al.  Celecoxib for the prevention of colorectal adenomatous polyps. , 2006, The New England journal of medicine.

[22]  I. Endo,et al.  Predicting 5‐fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: Three‐gene expression model predicts clinical response , 2006, International journal of cancer.

[23]  Yan Liu,et al.  Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. , 2006, Journal of the National Cancer Institute.

[24]  J. Manson,et al.  A prospective study of soluble tumor necrosis factor-alpha receptor II (sTNF-RII) and risk of coronary heart disease among women with type 2 diabetes. , 2005, Diabetes care.

[25]  Jing Ma,et al.  Inflammatory markers and the risk of coronary heart disease in men and women. , 2004, The New England journal of medicine.

[26]  Susan Halabi,et al.  A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. , 2003, The New England journal of medicine.

[27]  E. Kliewer,et al.  Cancer risk in patients with inflammatory bowel disease , 2001, Cancer.

[28]  J. Paik,et al.  Two opposing effects of non-steroidal anti-inflammatory drugs on the expression of the inducible cyclooxygenase. Mediation through different signaling pathways. , 2000, The Journal of biological chemistry.

[29]  B. Levin,et al.  The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.

[30]  S. Pignata,et al.  Effect of aspirin on cell proliferation and differentiation of colon adenocarcinoma Caco‐2 cells , 1997, International journal of cancer.

[31]  J. Manson,et al.  The Nurses' Health Study: 20-year contribution to the understanding of health among women. , 1997, Journal of women's health.

[32]  Paul D. Allison,et al.  Survival analysis using sas®: a practical guide , 1995 .

[33]  M Lunn,et al.  Applying Cox regression to competing risks. , 1995, Biometrics.

[34]  G. Tilz,et al.  Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis , 1995, European journal of haematology.

[35]  E. Rimm,et al.  Intake of fat, meat, and fiber in relation to risk of colon cancer in men. , 1994, Cancer research.

[36]  E. Rimm,et al.  Prospective study of alcohol consumption and risk of coronary disease in men , 1991, The Lancet.

[37]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[38]  W. Willett,et al.  Test of the National Death Index. , 1984, American journal of epidemiology.

[39]  P. Rothwell,et al.  Biological markers: Potential biomarker for aspirin use in colorectal cancer therapy , 2013, Nature Reviews Clinical Oncology.

[40]  Sandra D Fights,et al.  Nurses' Health Study. , 2011, Medsurg nursing : official journal of the Academy of Medical-Surgical Nurses.

[41]  P. Loehrer.  Celecoxib for the Prevention of Colorectal Adenomatous Polyps , 2008 .

[42]  J. Coebergh,et al.  Comorbidity and colorectal cancer according to subsite and stage: a population-based study. , 2000, European journal of cancer.